Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i As Triple Therapy with Type 2 Diabetes and Chronic Kidney Disease
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms RAiSiN
Most Recent Events
- 16 Dec 2024 New trial record